MedTrace Logo

Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

NCT00252239 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2015-03-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).

Conditions

Interventions

DRUG

tenecteplase

This study will compare 3 different doses of tenecteplase to tPA.

DRUG

tissue plasminogen activator, tPA

To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • University of Virginia

    lead OTHER

Principal Investigators

  • E. Clarke Haley, Jr., M.D. · Clinical Coordinating Center, Department of Neurology, University of Virginia Health System

  • John L. P. Thompson, Ph.D. · Statistical Analysis Center, Department of Biostatistics, Mailman School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-03-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252239 on ClinicalTrials.gov